NY A 2650
in committeeLimits the substitution of abuse-deterrent analgesic opioid drug products for analgesic opioids lacking such technology
New York · 2025-2026 Regular Session · lower
Quick answers
Did NY A 2650 pass?
Not yet. NY A 2650 is in committee as of 2026-01-07 and has not come to a final vote. Latest recorded action (2026-01-07): REFERRED TO INSURANCE
What is NY A 2650 about?
Provides for patient access to FDA approved abuse-deterrent technology to help combat opioid abuse.
Who sponsors NY A 2650?
Nader Sayegh is the primary sponsor of NY A 2650.
Description
Provides for patient access to FDA approved abuse-deterrent technology to help combat opioid abuse.
- Introduced
- —
- Latest action
- 2026-01-07 — REFERRED TO INSURANCE
- Bill type
- bill
- Last updated
- —
Sponsors
- Nader Sayeghprimary
Committees
Not provided by source.
Action timeline
2025-01-21
REFERRED TO INSURANCE
referral-committee
2026-01-07
REFERRED TO INSURANCE
referral-committee
Versions
- A2650Compare
Documents
Votes
Not provided by source.
Related bills
- Prior session: A 4667not in this corpus
- Prior session: A 62not in this corpus
- Companion bill: S 987
Official source
Attribution
Data from openstates_bulk_csv, retrieved 2026-07-24T05:28:30.722574Z
Inspect retained evidence for changes recorded after evidence tracking began:
Session-wide evidence can include changes to other bills:
Use this data
Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=NY&identifier=A 2650. See the API docs or the MCP server for AI assistants.
Known limitations
- Sponsor party and chamber affiliation are not yet captured by this API.
- Committee referrals are not yet captured.
See the methodology page for data sources and limitations.